KRAS and chronic hepatitis C virus infection: Currently, DAAs for NS3/4A protease, such as telaprevir and boceprevir, are being used to treat chronic hepatitis C [7, 8, 31], and other DAA candidates targeting NS5A or NS5B are waiting for approval [32–34].